Pre-made Yttrium (90Y) Tacatuzumab Tetraxetan benchmark antibody (Radiolabelled antibody, anti-AFP therapeutic antibody, Anti-AFPD/FETA/HPAFP Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Yttrium (90Y) Tacatuzumab Tetraxetan benchmark antibody (Radiolabelled antibody, anti-AFP therapeutic antibody, Anti-AFPD/FETA/HPAFP Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Yttrium (9Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-9,[2] a radioisotope which destroys the tumour cells.
| Products Name (INN Index) | Pre-Made Yttrium (90Y) Tacatuzumab Tetraxetan Biosimilar, Radiolabelled Antibody, Anti-Afp Antibody: Anti-AFPD/FETA/HPAFP therapeutic antibody |
|---|---|
| INN Name | yttrium (90Y) tacatuzumab tetraxetan |
| Target | AFP |
| Format | Radiolabelled antibody |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Immunomedics?Inc. (Morris Plains NJ USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | AFP |
| Package |
